GO:1903494 response to dehydroepiandrosterone: Steroid Hormone Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903494 (response to dehydroepiandrosterone) describes any cellular or organismal change triggered by the steroid hormone dehydroepiandrosterone (DHEA).
• DHEA is a major adrenal androgen precursor whose secretion is highly variable and ACTH-responsive in healthy women.
• The response to DHEA includes changes in gene expression, proliferation, and inflammatory signaling in hormone-sensitive tissues.
• DHEA and its sulfate ester DHEAS act through multiple molecular mechanisms, including steroid receptor modulation and neurosteroid activity.
• DHEA response is studied in polycystic ovary syndrome, prostate cancer, frailty, and stress-related conditions.
• CRISPR knockout, knock-in, and overexpression models enable causal testing of genes mediating the DHEA response.
Description
GO:1903494, response to dehydroepiandrosterone, is a biological process Gene Ontology term that captures any change in a cell or organism resulting from a dehydroepiandrosterone (DHEA) stimulus. DHEA is a steroid hormone precursor produced primarily by the adrenal cortex, and its sulfate ester DHEAS circulates at high concentrations in humans. The response to DHEA is physiologically important because DHEA and DHEAS influence gene expression, proliferation, inflammation, and neuroendocrine signaling across many tissues. Researchers study this process to understand adrenal steroid biology, sex-hormone precursor actions, and disease mechanisms ranging from polycystic ovary syndrome to prostate cancer and frailty. Because DHEA secretion is highly variable and ACTH-responsive, the response to DHEA is also a model for inter-individual variability in steroid hormone action. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:1903494, its mechanisms, key genes, disease relevance, and CRISPR-based experimental strategies.
response to dehydroepiandrosterone At A Glance
| GO ID | GO:1903494 |
|---|---|
| GO term | response to dehydroepiandrosterone |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a dehydroepiandrosterone stimulus. |
| Major function | Mediates cellular and organismal responses to the steroid hormone DHEA, including gene expression, proliferation, and inflammatory changes. |
| Related hormone | Dehydroepiandrosterone (DHEA) and its sulfate ester DHEAS. |
| Key physiological context | Adrenal steroidogenesis, ACTH responsiveness, and sex-hormone precursor actions. |
| Disease relevance | Polycystic ovary syndrome, prostate cancer, frailty, and stress-related conditions. |
What Is GO:1903494?
In our own words, GO:1903494 describes the collection of cellular and organismal responses that occur when a cell or organism encounters dehydroepiandrosterone. These responses can include changes in movement, secretion, enzyme production, gene expression, and other activities, as stated in the QuickGO definition. The term is a biological process and does not specify a single receptor or pathway; instead, it encompasses the diverse downstream effects of DHEA exposure.
Why Is response to dehydroepiandrosterone Important in Cell Biology?
Understanding GO:1903494 is important because DHEA is one of the most abundant circulating steroid hormones in humans and serves as a precursor for androgens and estrogens. The response to DHEA affects gene expression, cell proliferation, and inflammatory pathways in tissues such as the prostate, ovary, and brain. Clinically, altered DHEA responses have been linked to polycystic ovary syndrome, frailty in older women, and prostate cancer biology. Studying this process helps researchers dissect how steroid hormones modulate cell state and how inter-individual variability in adrenal steroid secretion contributes to disease.
• DHEA is a major adrenal androgen precursor with broad tissue effects.
• The response to DHEA includes changes in gene expression and proliferation in hormone-sensitive cells.
• DHEA modulates inflammatory responses, as shown in polycystic ovary syndrome models.
• DHEA and DHEAS act through multiple molecular mechanisms, including neurosteroid and receptor-mediated actions.
• DHEA secretion is highly variable and ACTH-responsive, making the response context-dependent.
• Altered DHEA responses are associated with frailty in older women.
• DHEA response is relevant to polycystic ovarian disease and adrenal steroid dysregulation.
• DHEA response pathways are studied in prostate cancer cell models.
• CRISPR models enable causal testing of genes mediating DHEA responses.
• The term supports research on steroid hormone action, endocrine disease, and inflammation.
What Happens During response to dehydroepiandrosterone?
DHEA Stimulus and Adrenal Secretion
In simple terms: DHEA is released by the adrenal glands, and its levels can change quickly in response to signals like ACTH.
The response to DHEA begins with the availability of the hormone. In healthy women, adrenocortical secretion of DHEA is highly variable and shows a marked response to adrenocorticotropin (ACTH). In children, plasma DHEA responds to corticotropin-releasing factor during pubertal development, indicating that the adrenal DHEA response is developmentally regulated. In dairy cows, DHEA and cortisol responses to an ACTH challenge differ between lame and nonlame animals, showing that physiological state can modify the DHEA response. These findings establish that the DHEA stimulus is dynamic and context-dependent.
Receptor and Signaling Events
In simple terms: Once DHEA reaches a cell, it can interact with receptors and signaling proteins that change what the cell does.
DHEA and its sulfate ester DHEAS act through multiple molecular mechanisms on the human body, including steroid receptor modulation and neurosteroid activity. The response to DHEA can involve changes in gene expression, as demonstrated in human LNCaP prostate cancer cells where DHEA treatment altered proliferation and gene expression compared with testosterone, dihydrotestosterone, and estradiol. These comparative effects indicate that DHEA engages distinct transcriptional programs rather than simply mimicking other sex steroids.
Transcriptional and Gene Expression Changes
In simple terms: DHEA exposure switches genes on or off, which changes how cells grow and behave.
A central feature of GO:1903494 is the change in gene expression that follows DHEA exposure. In LNCaP prostate cancer cells, DHEA treatment produced gene expression changes that were compared with those of testosterone, dihydrotestosterone, and estradiol, revealing both shared and unique transcriptional responses. In a rat model of DHEA-induced polycystic ovary syndrome, isorhamnetin inhibited the inflammatory response, indicating that DHEA exposure activates inflammatory gene programs that can be pharmacologically modulated. These studies show that the DHEA response includes measurable transcriptional and inflammatory outputs.
Proliferation and Cellular Outcomes
In simple terms: DHEA can make some cells grow faster or slower, depending on the tissue.
The response to DHEA includes changes in cell proliferation. In human LNCaP prostate cancer cells, DHEA was compared with testosterone, dihydrotestosterone, and estradiol for effects on proliferation and gene expression, demonstrating that DHEA can influence growth-related pathways in hormone-sensitive cancer cells. In DHEA-induced polycystic ovary syndrome in rats, the inflammatory response was a key outcome that contributed to the phenotype. These cellular outcomes illustrate how the DHEA response translates into functional changes relevant to disease.
Systemic and Clinical Responses
In simple terms: The body's response to DHEA can be measured in blood and linked to health conditions like frailty.
At the organismal level, the DHEA response can be assessed by measuring plasma DHEA after stimulation. In older women, cortisol and DHEA responses to ACTH were examined in relation to frailty, linking adrenal steroid responses to a geriatric syndrome. In polycystic ovarian disease, adrenal steroid responses to naloxone were studied, showing that DHEA is part of a broader adrenal steroid response network. These clinical studies demonstrate that GO:1903494 has measurable systemic manifestations.
Key Genes Involved in GO:1903494 response to dehydroepiandrosterone
The following genes and proteins are involved in or used to study the response to dehydroepiandrosterone (GO:1903494), based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AR | Androgen receptor; mediates androgen signaling that can be influenced by DHEA as a precursor | Studied in prostate cancer cells treated with DHEA |
| SRD5A1 | 5-alpha-reductase; converts testosterone to dihydrotestosterone, part of DHEA downstream metabolism | Relevant to DHEA conversion to active androgens |
| SRD5A2 | 5-alpha-reductase type 2; androgen metabolism | Potential target in DHEA response studies |
| CYP17A1 | Steroid 17-alpha-hydroxylase; adrenal steroidogenesis including DHEA production | Central to DHEA synthesis and response context |
| CYP11A1 | Cholesterol side-chain cleavage enzyme; first step in steroidogenesis | Upstream of DHEA production |
| HSD3B2 | 3-beta-hydroxysteroid dehydrogenase; steroidogenic enzyme | Part of adrenal steroid pathway |
| STAR | Steroidogenic acute regulatory protein; cholesterol transport | Supports DHEA synthesis |
| POMC | Pro-opiomelanocortin; precursor of ACTH that drives adrenal DHEA secretion | ACTH response studies |
| CRH | Corticotropin-releasing hormone; upstream regulator of ACTH and DHEA | Pubertal DHEA response studies |
| NR3C1 | Glucocorticoid receptor; cortisol signaling that interacts with DHEA responses | Frailty and stress studies |
| ESR1 | Estrogen receptor alpha; DHEA can be converted to estrogens | Compared with DHEA effects in prostate cancer cells |
| ESR2 | Estrogen receptor beta; estrogen signaling | Relevant to DHEA downstream effects |
| NFKB1 | NF-kB subunit; inflammatory signaling modulated by DHEA | DHEA-induced PCOS inflammation studies |
| IL6 | Interleukin-6; inflammatory cytokine | Inflammation readout in DHEA-induced PCOS |
| TNF | Tumor necrosis factor; inflammatory cytokine | Inflammation readout in DHEA-induced PCOS |
| GABRA1 | GABA-A receptor subunit; neurosteroid actions of DHEA | Neurosteroid mechanism studies |
| GRIN1 | NMDA receptor subunit; DHEA neurosteroid modulation | Neurosteroid mechanism studies |
How Is response to dehydroepiandrosterone Regulated?
The response to dehydroepiandrosterone is regulated at multiple levels. Adrenal DHEA secretion is stimulated by ACTH, and the magnitude of this response varies widely among healthy women. In children, CRH stimulates plasma ACTH, cortisol, and DHEA during pubertal development, indicating developmental regulation of the DHEA response. In dairy cows, the DHEA response to an ACTH challenge is influenced by lameness status, suggesting that physiological stress modulates the response. At the cellular level, DHEA and DHEAS act through multiple molecular mechanisms, including steroid receptor modulation and neurosteroid activity, which provide additional layers of regulation. Inflammatory signaling is also a regulatory node, as isorhamnetin inhibits the inflammatory response in DHEA-induced polycystic ovary syndrome in rats.
response to dehydroepiandrosterone and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFKB1 | Inflammation in DHEA-induced PCOS | Knockout in rat ovarian cells or PCOS model |
| AR | Prostate cancer proliferation and gene expression | Knockout or point mutation in LNCaP cells |
| ESR1 | Estrogen signaling in prostate cancer | Overexpression or knockout in LNCaP cells |
| NR3C1 | Frailty and adrenal steroid response | Knockout in adrenal or immune cells |
| IL6 | Inflammatory response in PCOS | Knockout in rat PCOS model |
Polycystic Ovary Syndrome (PCOS)
DHEA-induced polycystic ovary syndrome in rats is a model in which DHEA exposure triggers inflammatory responses that contribute to the phenotype. Isorhamnetin inhibits this inflammatory response, demonstrating that the DHEA response is causally linked to PCOS-like features and can be modulated pharmacologically. In women with polycystic ovarian disease, adrenal steroid responses to naloxone have been studied, further supporting a connection between adrenal DHEA responses and PCOS.
Prostate Cancer
In human LNCaP prostate cancer cells, DHEA treatment affects proliferation and gene expression, and its effects were compared with testosterone, dihydrotestosterone, and estradiol. This indicates that the response to DHEA is relevant to prostate cancer biology and that DHEA can act as a hormone precursor or signaling molecule in prostate cancer cells.
Frailty and Aging
In older women, cortisol and DHEA responses to ACTH were examined in relation to frailty, linking the adrenal DHEA response to a geriatric syndrome characterized by reduced physiological reserve. This suggests that altered DHEA responses may be a biomarker or mediator of frailty.
Stress and Adrenal Disorders
The DHEA response is part of the broader adrenal steroid response to stress. In dairy cows, DHEA and cortisol responses to an ACTH challenge differed between lame and nonlame animals, showing that the DHEA response is sensitive to physiological stress. In children, the DHEA response to CRH during pubertal development highlights the developmental regulation of this adrenal pathway.
From response to dehydroepiandrosterone-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene mediate DHEA-induced proliferation? | CRISPR knockout in LNCaP prostate cancer cells |
| Does a point mutation in AR alter DHEA response? | Point mutation knock-in in prostate cancer cell lines |
| Does overexpression of a steroidogenic enzyme enhance DHEA response? | Overexpression cell model |
| Does a tagged protein localize differently after DHEA treatment? | Tagged knock-in for imaging |
| Does loss of an inflammatory gene reduce DHEA-induced PCOS features? | Knockout in rat PCOS model |
| Does a candidate gene affect adrenal DHEA secretion? | Knockout in adrenal cell models |
How to Study the response to dehydroepiandrosterone Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | DHEA-treated prostate cancer cells |
| ELISA | Plasma DHEA and cortisol levels | ACTH challenge studies |
| LC-MS | Steroid hormone quantification | Adrenal steroid profiling |
| CRISPR knockout | Loss-of-function effects on DHEA response | Candidate gene validation |
| CRISPR activation (CRISPRa) | Gain-of-function effects | Overexpression of steroidogenic genes |
| Cytokine assays | Inflammatory response | DHEA-induced PCOS model |
| Immunofluorescence | Protein localization after DHEA treatment | Tagged knock-in imaging |
| Western blot | Protein expression and signaling | DHEA response pathway analysis |
Transcriptomic Profiling (RNA-seq)
RNA sequencing can measure global gene expression changes after DHEA treatment. In LNCaP prostate cancer cells, DHEA treatment altered gene expression compared with other sex steroids, and RNA-seq would provide a comprehensive view of these transcriptional responses. This method is useful for identifying pathways downstream of GO:1903494.
Inflammatory Cytokine Assays
Because DHEA-induced PCOS involves an inflammatory response, measuring cytokines such as IL6 and TNF can quantify the DHEA response. Isorhamnetin inhibition of this response provides a positive control for assay development.
Hormone Measurements (ELISA, LC-MS)
Plasma DHEA and cortisol responses to ACTH or CRH are measured by immunoassay or mass spectrometry in clinical and animal studies. These methods are essential for quantifying the stimulus and response in vivo.
CRISPR Screening and Functional Genomics
CRISPR library screening can identify genes required for the DHEA response. By treating cells with DHEA and selecting for proliferation or survival, researchers can enrich for sgRNAs targeting mediators of GO:1903494. This approach is hypothesis-generating and complements targeted knockout studies.
How CRISPR Can Be Used to Study GO:1903494 response to dehydroepiandrosterone
Knockout
CRISPR knockout can delete candidate genes to test whether they are required for the DHEA response. For example, knocking out inflammatory genes in a DHEA-induced PCOS rat model could determine whether they mediate the inflammatory response. In prostate cancer cells, knocking out AR or ESR1 could reveal their roles in DHEA-induced proliferation and gene expression.
Point Mutation
Point mutation knock-in can model specific amino acid changes in receptors or enzymes involved in the DHEA response. For instance, mutations in AR that alter ligand specificity could be introduced into prostate cancer cells to study DHEA responsiveness. This approach helps distinguish between different signaling mechanisms.
Knock-in
Knock-in of tagged proteins allows visualization and biochemical isolation of components of the DHEA response. Tagging steroidogenic enzymes or receptors can reveal their localization and interactions after DHEA treatment. This is particularly useful for studying neurosteroid mechanisms.
Overexpression
Overexpression of steroidogenic enzymes or receptors can enhance the DHEA response and test sufficiency. For example, overexpressing CYP17A1 or SRD5A1 could increase DHEA production or metabolism in cell models. Overexpression of inflammatory mediators could exacerbate DHEA-induced PCOS phenotypes.
How EDITGENE Supports response to dehydroepiandrosterone Research
Researchers studying response to dehydroepiandrosterone-related genes often need to determine whether a candidate gene is causally involved in the cellular and organismal changes triggered by DHEA. EDITGENE provides CRISPR-based cell model services that enable loss-of-function, gain-of-function, and precise mutation studies to dissect GO:1903494 mechanisms.
Contact EDITGENE today to design your custom CRISPR model for response to dehydroepiandrosterone research.
Frequently Asked Questions About response to dehydroepiandrosterone
What is GO:1903494?
GO:1903494 is the Gene Ontology term for response to dehydroepiandrosterone, defined as any process that results in a change in state or activity of a cell or organism as a result of a DHEA stimulus.
What is response to dehydroepiandrosterone?
It is the collection of cellular and organismal changes triggered by DHEA, including gene expression, proliferation, and inflammatory responses.
What genes are involved in response to dehydroepiandrosterone?
Genes include AR, ESR1, ESR2, CYP17A1, SRD5A1, SRD5A2, NFKB1, IL6, TNF, and others involved in steroidogenesis and inflammation.
How is DHEA response measured?
It is measured by plasma DHEA and cortisol assays after ACTH or CRH stimulation, as well as by gene expression and cytokine assays in cell models.
What diseases are linked to DHEA response?
Polycystic ovary syndrome, prostate cancer, frailty, and stress-related adrenal conditions have been linked to DHEA responses.
What is the role of DHEA in polycystic ovary syndrome?
DHEA induces a PCOS-like phenotype in rats, and inflammatory responses contribute to this phenotype, which can be inhibited by isorhamnetin.
How does DHEA affect prostate cancer cells?
DHEA treatment alters proliferation and gene expression in LNCaP prostate cancer cells, with effects compared with testosterone, dihydrotestosterone, and estradiol.
Is DHEA response the same in all people?
No, adrenocortical secretion of DHEA in healthy women is highly variable and ACTH-responsive, indicating inter-individual differences.
What CRISPR models are used to study DHEA response?
Knockout, point mutation, knock-in, and overexpression models in hormone-sensitive cell lines and animal models are used.
Why is DHEA response important for aging research?
DHEA responses to ACTH have been linked to frailty in older women, suggesting a role in aging and physiological reserve.
Conclusion
GO:1903494, response to dehydroepiandrosterone, is a biologically important process that encompasses the diverse cellular and organismal changes triggered by DHEA. From adrenal secretion and receptor signaling to transcriptional, proliferative, and inflammatory outcomes, the DHEA response is relevant to polycystic ovary syndrome, prostate cancer, frailty, and stress-related conditions. CRISPR-based models provide powerful tools to dissect the causal genes and pathways underlying this response. Continued research using these approaches will clarify how DHEA shapes cell state and disease.
References
- 1. Le NP et al.. 2021. Cortisol and Dehydroepiandrosterone Response to Adrenocorticotropic Hormone and Frailty in Older Women.. J Gerontol A Biol Sci Med Sci 76(5):901-905 PMID: 32502234
- 2. Lin HY et al.. 2025. The Sex Hormone Precursors Dehydroepiandrosterone (DHEA) and Its Sulfate Ester Form (DHEAS): Molecular Mechanisms and Actions on Human Body.. Int J Mol Sci 26(17) PMID: 40943486
- 3. Azziz R et al.. 2001. Adrenocortical secretion of dehydroepiandrosterone in healthy women: highly variable response to adrenocorticotropin.. J Clin Endocrinol Metab 86(6):2513-7 PMID: 11397848
- 4. Jurkovich V et al.. 2020. Cardiac vagal tone, plasma cortisol, and dehydroepiandrosterone response to an ACTH challenge in lame and nonlame dairy cows.. Domest Anim Endocrinol 71:106388 PMID: 31821929
- 5. Arnold JT et al.. 2005. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.. Am J Physiol Endocrinol Metab 288(3):E573-84 PMID: 15536203
- 6. D'Ambrogio G et al.. 1987. Adrenal steroid responses to naloxone in polycystic ovarian disease.. Gynecol Endocrinol 1(4):355-61 PMID: 2845715
- 7. Attanasio A et al.. 1987. Plasma adrenocorticotropin, cortisol, and dehydroepiandrosterone response to corticotropin-releasing factor in normal children during pubertal development.. Pediatr Res 22(1):41-4 PMID: 2819816
- 8. Yu F et al.. 2023. Isorhamnetin inhibits inflammatory response to alleviate DHEA-induced polycystic ovary syndrome in rats.. Gynecol Endocrinol 39(1):2183045 PMID: 36842967
